Journal
CURRENT DRUG TARGETS
Volume 21, Issue 5, Pages 477-498Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450120666191021110208
Keywords
ROS; programmed cell death; bone marrow protection; chemotherapy; tumor; hematopoiesis
Categories
Funding
- Public Welfare Technology Application Research Project of Zhejiang Province, Zhejiang, China [2015C37122]
- Zhejiang Provincial Natural Science Foundation of China, Zhejiang, China [LY17H160003]
Ask authors/readers for more resources
Reactive oxygen species (ROS), an important molecule inducing oxidative stress in organisms, play a key role in tumorigenesis, tumor progression and recurrence. Recent findings on ROS have shown that ROS can be used to treat cancer as they accelerate the death of tumor cells. At present, pro-oxidant drugs that are intended to increase ROS levels of the tumor cells have been widely used in the clinic. However, ROS are a double-edged sword in the treatment of tumors. High levels of ROS induce not only the death of tumor cells but also oxidative damage to normal cells, especially bone marrow hemopoietic cells, which leads to bone marrow suppression and (or) other side effects, weak efficacy of tumor treatment and even threatening patients' life. How to enhance the killing effect of ROS on tumor cells while avoiding oxidative damage to the normal cells has become an urgent issue. This study is a review of the latest progress in the role of ROS-mediated programmed death in tumor treatment and prevention and treatment of oxidative damage in bone marrow induced by ROS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available